ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

Abstract

Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the prevention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin ± Lactobacillus (B-II). The treatment of IC in neonates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system. Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafungin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole (A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B (A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used.

Antifungal activity of Terminalia superba (combretaceae)

“…Ultimately, the F3 fraction shows the highest antifungal activity of TEKAM4-X0. Furthermore, the activities of X0, X1-1, X1-2 and the three fractions (F1, F2, F3) tested could be considered as very important since the C. albicans strain tested was resistant to commonly used antifungal drugs (Kah, 2011 ;Hope et al, 2012).…”

Fungal Infections in Newborn

“…Üniteler antifungal direnci açısından sürveyans çalışmalarını düzenli yapmalıdırlar (47). Çalışmaların biriken sonuçlarına göre, flukonazol proflaksisi kandidiyazisi önlemede etkin ve güvenli görünmektedir.…”

Candidiasis invasoras en recién nacidos: diagnóstico, tratamiento y prevención

“…Con el uso de L-amB no se describen efectos adversos significativos, salvo hipokalemia leve que se recupera pronto con el aporte de potasio [35][36][37] . Un grupo de expertos de la Sociedad Europea de Microbiología Clínica e Infectología (ESCMID) se refiere al uso de L-amB, en dosis de 2,5 a 7 mg/kg/día en RN con un adecuado perfil de seguridad 38 . Los estudios con ABCL y ABDC son escasos 39,40 .…”

“…En aquellas unidades donde la incidencia es baja (< 2%) la sugerencia es realizar una evaluación de cada caso en particular según los factores de riesgo que posea el RN 38 , teniendo una consideración especial el grupo de RNpret extremo con alta tasa de colonización (≥ 3 sitios anatómicos) 68 .…”